• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Quanta wins UK grant for nocturnal hemodialysis device

Quanta wins UK grant for nocturnal hemodialysis device

August 21, 2015 By Fink Densford

Quanta wins UK grant for nocturnal hemodialysis device

Quanta Fluid Solutions said Tuesday it won a $2.9 million (UK £1.85 million) grant from the U.K.’s National Institute for Health Research to support a new nocturnal hemodialysis product.

The grant will go towards the development of a new dialysis machine concept that is specifically designed for nocturnal use, Quanta said. With the funds, Quanta is slated to develop a series of new technologies to optimize the delivery of nocturnal dialysis.

“We are excited to have been awarded i4i funding from the NIHR.  This will enable us to develop our product offering in promising new directions and to investigate the potential of new technologies for a nocturnal system designed to bring even greater benefits to renal patients.   The i4i award is a validation of Quanta’s vision and capacity for innovation in dialysis technologies.  We look forward to working with Sheffield University and Europlaz Technologies in developing this new concept,” CEO John Milad said in a press release.

Quanta will be collaborating with William Zimmerman of Sheffield University’s department of chemical and biological engineering and Europlaz Technologies for the project. The team at Sheffield University will contribute towards multi-physics modeling of haemodialysis and Europlaz will aid in the development of technologies to be used in designing disposable cartridges for the system.

“We believe that, with NIHR funding and the work Quanta is already doing in the dialysis space, SC+ has the potential to change the way dialysis patients are treated. Our award validates the unique positioning of i4i in de-risking early stage, innovative technologies for later stage investment. The addition of a nocturnal system would give patients even more flexibility and control over their treatment options and we are looking forward to seeing the results of this promising project,” NIHR i4i program director Martin Hunt said in prepared remarks.

Nocturnal dialysis is generally a long overnight treatment that more accurately imitates natural kidney function and is gentler on the body, Quanta said. Frequent nocturnal dialysis has been shown to increase 5-year survivability comparable to donor transplants, the company said.

Filed Under: Blood Management, Business/Financial News, Dialysis, Research & Development Tagged With: Quanta Fluid Solutions

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy